Canada, Germany and Norway are discussing the possibility of a trilateral defence and security partnership covering the North Atlantic and the Arctic — an arrangement that could be broader and deeper ...

Prime Minister Narendra Modi and Nigerian President Bola Ahmed Tinubu on Sunday agreed to work together to meet the development aspirations of the Global South and, at the same time, further strengthe...

Pakistan, Saudi Arabia and Somalia are deepening defense ties as the fight for Somali sovereignty intensifies, reshaping the Horn of Africa, Red Sea security and the Somaliland dispute

Here's how to watch Zee TV from outside India, and learn how to access streams from anywhere abroad with a VPN.

Here's how to watch Zee TV from outside India, and learn how to access streams from anywhere abroad with a VPN.

Background The present study evaluated the real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR + /HER2-) metastatic breast cancer. Method This study was conducted on the HR + /HER2- metastatic breast cancer patients who received palbociclib/ ribociclib in the first line or recurrent setting between January 2021 and January 2023 along with endocrine therapy. Data was retrieved from the Hospital medical records. Results In the patients receiving palbociclib, a better median progression free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). Similarly, in the patients receiving ribociclib, a better median PFS was observed in patients with ECOG PS 1 (22.2 months,p-value <0.0001), de novo disease (21.7 months,p-value 0.0042), first-line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (21.7 months,p-value <0.0001). On multivariate analysis, ECOG PS, line of hormone therapy and prior chemotherapy showed significance (p-values <0.0001, < 0.0001 & 0.0269, respectively). Conclusion The study shows real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in metastatic breast cancer in India.

Background The present study evaluated the real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR + /HER2-) metastatic breast cancer. Method This study was conducted on the HR + /HER2- metastatic breast cancer patients who received palbociclib/ ribociclib in the first line or recurrent setting between January 2021 and January 2023 along with endocrine therapy. Data was retrieved from the Hospital medical records. Results In the patients receiving palbociclib, a better median progression free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). Similarly, in the patients receiving ribociclib, a better median PFS was observed in patients with ECOG PS 1 (22.2 months,p-value <0.0001), de novo disease (21.7 months,p-value 0.0042), first-line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (21.7 months,p-value <0.0001). On multivariate analysis, ECOG PS, line of hormone therapy and prior chemotherapy showed significance (p-values <0.0001, < 0.0001 & 0.0269, respectively). Conclusion The study shows real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in metastatic breast cancer in India.

French President Emmanuel Macron wrapped up the first day of a state visit to India on February 17, 2026, elevating defence cooperation with Indian Prime Minister Narendra Modi and setting out an expanded industrial and military roadmap.

As the curtain falls on the 2015-era defence pact, the new 10-year US-India Major Defence Partnership Framework ushers

In a world increasingly defined by alliances and deterrence, AUSTRAHIND is more than a military exercise — it’s a commitment to a shared

India and Australia held their first Defence Ministers’ Dialogue in Canberra, marking a new phase in strategic and maritime cooperation

Lockheed Bengaluru Defense Will Enhance Partnership With US: Report.